Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.
Reduced forced vital capacity in Aboriginal Australians: Biology or missing evidence?
Hall GL, Pearson G.
Respirology. 2015 Jul;20(5):693-4. doi: 10.1111/resp.12552. Epub 2015 May 18.
PMID:25988308
Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.
Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A.
J Neurol. 2019 Sep;266(9):2312-2321. doi: 10.1007/s00415-019-09401-1. Epub 2019 Jun 11.
PMID:31187190
Changes in forced vital capacity over 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.
Berger KI, Chien YH, Dubrovsky A, Kishnani PS, Llerena JC Jr, Neilan E, Roberts M, Sheng B, Batista JL, Periquet M, Wilson KM, van der Ploeg AT.
J Neurol. 2024 Aug;271(8):5433-5446. doi: 10.1007/s00415-024-12489-9. Epub 2024 Jun 19.
PMID:38896264
Prediction of forced vital capacity with dynamic chest radiography in interstitial lung disease.
Ueyama M, Hashimoto S, Takeda A, Maruguchi N, Yamamoto R, Matsumura K, Nakamura S, Terada S, Inao T, Kaji Y, Yasuda T, Hajiro T, Tanaka E, Taguchi Y, Noma S.